Madama Daniela, Martins Rosana, Pires Ana S, Botelho Maria F, Alves Marco G, Abrantes Ana M, Cordeiro Carlos R
Clinical Academic Center of Coimbra (CACC), Department of Pulmonology, Faculty of Medicine, University Hospitals of Coimbra, University of Coimbra, 3004-504 Coimbra, Portugal.
Coimbra Institute for Clinical and Biomedical Research (iCBR), Biophysics Institute of Faculty of Medicine of University of Coimbra, Area of Environmental Genetics and Oncobiology (CIMAGO), 3000-548 Coimbra, Portugal.
Metabolites. 2021 Sep 17;11(9):630. doi: 10.3390/metabo11090630.
Lung cancer continues to be a significant burden worldwide and remains the leading cause of cancer-associated mortality. Two considerable challenges posed by this disease are the diagnosis of 61% of patients in advanced stages and the reduced five-year survival rate of around 4%. Noninvasively collected samples are gaining significant interest as new areas of knowledge are being sought and opened up. Metabolomics is one of these growing areas. In recent years, the use of metabolomics as a resource for the study of lung cancer has been growing. We conducted a systematic review of the literature from the past 10 years in order to identify some metabolites associated with lung cancer. More than 150 metabolites have been associated with lung cancer-altered metabolism. These were detected in different biological samples by different metabolomic analytical platforms. Some of the published results have been consistent, showing the presence/alteration of specific metabolites. However, there is a clear variability due to lack of a full clinical characterization of patients or standardized patients selection. In addition, few published studies have focused on the added value of the metabolomic profile as a means of predicting treatment response for lung cancer. This review reinforces the need for consistent and systematized studies, which will help make it possible to identify metabolic biomarkers and metabolic pathways responsible for the mechanisms that promote tumor progression, relapse and eventually resistance to therapy.
肺癌仍然是全球范围内的一个重大负担，并且依然是癌症相关死亡的主要原因。这种疾病带来的两个重大挑战是，61%的患者在晚期才被诊断出来，以及五年生存率降低至约4%。随着新的知识领域不断被探索和开拓，非侵入性采集的样本正引起人们极大的兴趣。代谢组学就是这些不断发展的领域之一。近年来，将代谢组学用作肺癌研究资源的情况一直在增加。我们对过去10年的文献进行了系统综述，以确定一些与肺癌相关的代谢物。超过150种代谢物与肺癌改变的代谢有关。它们通过不同的代谢组学分析平台在不同的生物样本中被检测到。一些已发表的结果具有一致性，显示出特定代谢物的存在/改变。然而，由于缺乏患者的全面临床特征描述或标准化的患者选择，存在明显的变异性。此外，很少有已发表的研究关注代谢组学图谱作为预测肺癌治疗反应手段的附加价值。这篇综述强化了进行一致且系统化研究的必要性，这将有助于识别负责促进肿瘤进展、复发以及最终产生治疗抗性机制的代谢生物标志物和代谢途径。
